|Description||ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50: 38 nM.|
|Synonyms||UNII-9EPS75QMTL; ORM-15341; 9EPS75QMTL; SCHEMBL1815556; GMBPVBVTPBWIKC-NSHDSACASA-N; CS-5191|
|Solubility||DMSO: ＞ 37 mg/mL|
|Application||ORM-15341 is an androgen receptor antagonist that could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50...
RAD140, an effective non-steroidal selective androgen receptor modulator, could probably stimulate the increasing of muscle and also has been found to have pote...
Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist as well as a weak progesterone receptor ago...
GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phas...
CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It ...
RU 58841 is a new non-steroidal antiandrogen which has potential for use in treating androgen-dependent skin disorders such as acne, hirsutism and androgen-depe...
Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM. It inhibits the activity of prostate cancer cell Ars, which over expressed in prostate ...
Spironolactone is a potent antagonist of the androgen receptor with IC50 of 77 nM.
MI-136, with the potential to treat refractory prostate cancer, inhibits DHT-induced expression of androgen receptor (AR) target genes. In vitro: Treatment with...
AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...
GLPG0492, a selective androgen receptor modulator, could be effective in decreasing muscle loss. The treatment study against Duchenne muscular dystrophy of it h...
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.
Cortexolone 17 alpha-propionate
Cortexolone 17 alpha-propionate, also called as CB-03-01, belonging to the family of ester derivatives of cortexolone, is a potent and topical and peripherally ...
LGD-2226 is a selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis, shows to have an anabolic effect on muscle and bon...
Fasobegron acts a β3-adrenoreceptor agonist.
LGD-4033, also known as VK5211 and Ligandrol, is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wast...
JNJ-26146900 is a selective, nonsteroidal androgen receptor modulator with tissue-selective activity in rats. It can bind to the rat AR with a Ki of 400nM and a...
GLPG0492 R enantiomer
The R-enantiomer of GLPG0492 which is a selective androgen receptor modulator, could be effective in decreasing muscle loss.
BX341, also known as bifluranol, is a new fluorinated bibenzyl anti-androgen and one of a series of bibenzyls designed to present some of the hormonal propertie...
ASC-J9 is an AR degradation enhancer, suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen rece...